Wanted also to say that the problem now as they have turned the corner is that the stock just isn't known. But I have a hunch it is starting to be researched and evaluated.
JMHO but I think a solid uptrend will soon ensue in the price of LUNA stock. I follow and invest in a lot of companies and this one is severley undervalued in place and time given their turn-arouns and portfolio of tecdhnologies. Their products that they are selling today are ramping.
Excellent earnings-the turnaround has clealry begun. Backlog growth is what really impressed me. If the market understood this company it would be trading over 10. The intellectual property alone is worth that much.
At 3 the co is way too cheap. Someone figuring out the value of their enterprise cloud and their place in the Indian market.
I like their portal sify.com also.
I disagree. They are now ramping customers and seeing signs of utility spending. stock is very cheap when you consider they will reach a critical mass sometime in 2011.
Very informative research they did IMHO. I like the oxidative stress study a lot.
And Lantus is at Ph-4 and therefor causes stinging pain at injection site. LinJeta is now Ph-7 an dnot 4. No more pain. The bridging study is part of the NDA. read link below where lantus users talk about their injection pain.
I agree with you. The clinical need is very real and significant-even the Pres. of The American Association of Diabetes thinks so.
today is being looked at more than only a test for glucose levels, but also the ability to establish good glucose control while avoiding hypoglycemia, dramatic excursions in blood glucose and weight gain", said Dr. Richard M. Bergenstal, president-elect of Medicine and Science for the American Diabetes Association in Alexandria, Va.
"A very rapid-acting insulin may be able to address many if not all of these factors," he said. "That is what we will be looking for in the data analysis of the Biodel product or other companies' efforts at making a very rapid-acting insulin."
Exactly-also something to consider is this. If you do not accept the Indian data as an anomoly you are essentially saying that insulin does not work because it as the "control arm" didn't work. There is a reason for contols in science and in trials.